Psilocybin Legal Status
31M lifetime US psilocybin users
Psilocybin is now the second most-used illicit substance in the United States, and the Netherlands truffle market, operating openly since 2008, is one of the few legal-access points in the Western world.
Jones et al., Annals of Internal Medicine, 2025
12.1%
of American adults have used psilocybin lifetime, up from 10% in 2019
2.1%
past-year US psilocybin use in 2023, double the 2019 rate
188%
increase in psilocybin use among Americans over 30 between 2019 and 2023
Jones et al., Annals of Internal Medicine, 2025
View as image ↗Magic truffles are openly for sale in Amsterdam. Walk into any of the city's smart shops and you can legally buy them, take them out the door, and use them without breaking Dutch law. Magic mushrooms, sold in those same shops until 2008, are now banned. The difference between what is legal and what is prohibited comes down to one biological fact: where in the fungus's life cycle the psilocybin is stored.
This is not a gray area that authorities are quietly tolerating while they build a case. It is the tested, court-affirmed legal status of psilocybin-containing fungal sclerotia in the Netherlands, a status created not by intentional drug reform but by legislative language that covered only half of the organism. This article covers how that happened and what it built. The broader history of how psilocybin became scheduled in the first place is in Psilocybin's Schedule I Status: History and Controversy, and how different countries have arrived at different legal positions from that baseline is documented in Psilocybin Legal Status Around the World: A Complete Guide.
Key Takeaways
- Magic mushrooms were banned in the Netherlands in December 2008 after a 17-year-old French tourist died in Amsterdam; the Opium Act amendment covered only the fruiting body ("paddenstoelen")
- Sclerotia, the underground storage tissue of certain Psilocybe species, were not listed in the amendment, and Dutch courts have consistently upheld that omission as legally binding
- Smart shops pivoted to truffle sales within days of the mushroom ban; the industry never stopped operating
- Three species dominate the market: Psilocybe tampanensis (Philosopher's Stones), P. mexicana, and P. atlantis, each sold at different labeled potency levels
- Amsterdam now hosts an openly operating retreat sector using truffles; international operators including Beckley Retreats run structured programs at the city's licensed venues
- Jones et al. (2025) found 31 million Americans have used psilocybin lifetime, up from 25 million in 2019, making the Netherlands one of the few legal-access points available to an internationally mobile user population
The Death That Triggered the Ban, and the Law That Left a Gap
On May 26, 2008, a 17-year-old French tourist named Gaëlle Caroff jumped from a building in Amsterdam. She had used magic mushrooms earlier that day. Her death generated immediate media attention across France and the Netherlands, and created concentrated political pressure on the Dutch cabinet.
The Netherlands had debated banning magic mushrooms twice before, in 2002 and again in 2007, without a vote. The Caroff case changed the political calculation. Within weeks of the incident, the cabinet approved an emergency amendment to the Opium Act.
The amendment added psilocybin mushrooms to Schedule I. The specific language used the Dutch word "paddenstoelen," which refers botanically to the fruiting body of the fungus: the cap and stem that grows above ground. The amendment listed the psychoactive compounds present in paddenstoelen (psilocine, psilocybine, baeocystine) and applied to any mushroom containing them.
Sclerotia were not mentioned.
Whether this was a deliberate accommodation for smart shop operators already pivoting their business model, or a straightforward legislative oversight, remains debated in Dutch drug policy circles. Several shop owners and legal advisers have said privately that the omission was noticed during the amendment's passage and that no one moved to correct it. The practical outcome was clear: on December 1, 2008, the day the ban took effect, most Amsterdam smart shops had already replaced their mushroom inventory with Psilocybe sclerotia.
Magic Truffles vs. Magic Mushrooms: Why Dutch Law Treats Them Differently
The word "truffle" in "magic truffles" is marketing, not botany. True truffles belong to a different family of fungi entirely. What Dutch shops sell as magic truffles are sclerotia: compact, hardened masses of fungal tissue that certain Psilocybe species produce underground, primarily as a survival mechanism.
Think of sclerotia as the fungus's emergency reserves. When conditions turn cold or dry, the organism can draw on these dense nutrient stores rather than dying. Psilocybe tampanensis produces sclerotia readily. So do P. mexicana and P. atlantis. The underground tissue stores psilocybin in concentrations comparable to the fruiting bodies produced by the same plant.
Chemically, there is no meaningful distinction in what reaches the brain. The same compound acts on the same receptor systems whether it came from a mushroom cap or an underground sclerotium. The pharmacological experience is produced by psilocybin regardless of what part of the fungus contained it.
The legal distinction, however, is absolute. The fruiting body is on Schedule I. The underground storage organ is not scheduled. A Psilocybe tampanensis specimen growing in a pot, with sclerotia underground and a tiny mushroom emerging above, is simultaneously an illegal substance in its upper half and an unscheduled one in its lower half, depending on which part you are in possession of.
Dutch courts have reviewed this precise question. Their rulings have been consistent: sclerotia are not paddenstoelen, and the Opium Act as written covers paddenstoelen. The prosecution's argument that sclerotia should be understood as functionally equivalent to mushrooms for the purposes of the scheduling language has not prevailed. The text says what it says.
How the Smart Shop Industry Pivoted in Days
Amsterdam's smart shop sector had been selling fresh and dried magic mushrooms since the mid-1990s. The shops operated in a regulated commercial ecosystem alongside coffee shops (licensed cannabis retailers) and herbal supplement stores, within a Dutch harm-reduction framework that treated controlled access as preferable to street markets for certain soft drugs.
When the cabinet announced the Opium Act amendment in mid-2008, smart shop owners and their legal counsel read the legislative text with close attention. The analysis was not complicated: mushrooms were being scheduled; sclerotia were not mentioned. Shop operators began placing orders for truffle-producing mycelium cultures from Dutch cultivators who had anticipated the transition.
By December 1, the changeover was largely complete. Some shops kept fresh mushrooms on the shelves until the final hours of November 30, then rolled in refrigerators stocked with vacuum-sealed truffle varieties. The product changed. The legal exposure changed completely. The counter staff, the prices, and the customers remained the same.
Today, Dutch smart shops sell fresh sclerotia in sealed packets at various potency grades, typically priced between 10 and 20 euros for a 15-gram portion. Shops are required to verify customer age and may not sell to minors. Most maintain printed harm-reduction materials and dosing information near the display. The operations are entirely above ground, with storefronts on main commercial streets in Amsterdam, Rotterdam, Utrecht, and most other Dutch cities. Online retailers also ship domestically with next-day delivery.
The Dutch government has not mounted a serious effort to close the legal gap since 2008. Trade organizations representing smart shops maintain working relationships with relevant ministries. The practical stability of the commercial sector, combined with the Dutch policy tradition of pragmatic tolerance, makes disruption unlikely in the near term.
The Three Truffle Species: What's for Sale and How They Differ
Three species dominate the Dutch commercial truffle market. Each has distinct cultivation characteristics and is marketed at different potency levels.
Psilocybe tampanensis produces the sclerotia sold under the Philosopher's Stones name. The species was first isolated in Tampa, Florida in 1977 by mycologist Steven Pollock, who grew the original specimens from a wild collection. Pollock was killed in 1981, and the strain was nearly lost when his laboratory was looted after his death. The Dutch commercial supply runs primarily on descendants of a single surviving isolate distributed by Amsterdam growers in the late 1990s and early 2000s. Tampanensis sclerotia have a moderate psilocybin content and are typically sold as the entry-level variety for first-time buyers. A 15-gram dose is considered standard.
Psilocybe mexicana was the species Albert Hofmann used in his foundational 1958 research, the work in which he first isolated psilocybin as a discrete compound. Mexicana produces relatively small sclerotia compared to tampanensis, but the plants are reliable under cultivation. Dutch shops label mexicana truffles as moderate to moderately strong.
Psilocybe atlantis is the highest-potency variety commonly stocked. Atlantis sclerotia are larger and denser than tampanensis, and independent laboratory analyses have measured higher psilocybin concentrations per gram in atlantis than in the other two main commercial species. Shops typically position atlantis as the experienced-user option.
Truffles are sold fresh, which affects dosing calculations. Dried psilocybin mushrooms typically contain 0.5 to 1.5 percent psilocybin by dry weight. Fresh sclerotia have higher water content, so the effective psilocybin per gram on a wet-weight basis is lower than in dried mushrooms, but the dose is adjusted upward accordingly. Shop staff commonly recommend 15 grams of fresh truffles as a moderate dose and 25 to 30 grams as a stronger one.
The Retreat Sector: Structured Programs Operating Openly
The Netherlands' position as the most accessible legal-access jurisdiction in Western Europe has created a secondary industry: structured psilocybin experiences marketed explicitly as therapeutic or ceremonial retreats, operating legally and openly in Amsterdam.
These are not underground operations. Retreat companies maintain websites with Amsterdam addresses, post session schedules publicly, and charge prices ranging from a few hundred euros for a day group session to several thousand euros for multi-day personal programs. Their clients are overwhelmingly international: Americans, British nationals, Germans, and Australians who cannot access psilocybin legally at home.
Beckley Retreats, associated with the Beckley Foundation research organization founded by Amanda Feilding, runs structured programs in Amsterdam using truffles as the psilocybin source. The format mirrors a clinical-adjacent model: pre-session psychological preparation, licensed therapists or facilitators present during the experience, and post-session integration work. Full program costs run several thousand euros per participant.
Other operators offer a simpler structure: a guided group session in a rented space, truffles supplied, a facilitator present, no extensive preparation requirement. These programs are not medically supervised. The Netherlands has no licensing requirement for psilocybin facilitators, no accreditation framework for retreat operators, and no regulatory body governing the quality or safety of these sessions. The legal basis for the entire retreat sector is simply that the substance they use is not scheduled.
For people in the US researching available options, legal psilocybin access before FDA approval now includes several pathways, and the Netherlands offers one that is genuinely accessible: commercial flights from most US hubs, no customs questions about substances, and a commercial infrastructure that has been operating continuously for 15 years.
The Dutch model sits in contrast to two other unregulated access points. Jamaica, where psilocybin has never been listed in the Dangerous Drugs Act, similarly hosts a retreat industry with no licensing framework; that situation is covered in Psilocybin in Jamaica: Legal Status and Retreat Industry. Australia rescheduled psilocybin as a prescription medicine in 2023, making it the first national government to formally recognize it as a therapeutic substance, but treatment costs run $15,000 to $25,000 AUD per full course and require authorized prescribers. The Netherlands model has no formal therapeutic framework at all; it operates purely because the substance is unscheduled. The Australia situation is covered at Australia's TGA Approval: The First Country to Prescribe Psilocybin.
What the Research Shows About Legal Access Effects
The Netherlands truffle market constitutes an informal natural experiment in what happens when psilocybin is openly available over an extended period. Dedicated academic study of the Dutch market specifically is sparse, but two recent papers document what happens when legal barriers drop in other contexts.
Bhave and colleagues published a 2025 study on the effects of Denver's 2019 decriminalization, the first US city to deprioritize personal psilocybin possession to the lowest law-enforcement priority.[1] They found that psilocybin use did increase after decriminalization. Most new users cited mental health self-treatment as the motivation. There was no associated increase in public safety incidents, no measurable rise in crime linked to psilocybin, and no documented public health emergency. The pattern of use that emerged, self-directed and mental-health-motivated, mirrors what informal reports suggest has characterized the Dutch truffle market for years.
The national picture comes from Jones et al., whose 2025 analysis in the Annals of Internal Medicine tracked psilocybin use across the United States between 2019 and 2023.[2] Lifetime use climbed from 25 million Americans (10% of adults) to 31 million (12.1%). Past-year use doubled from roughly 1% to 2.1%. The fastest growth came from adults over 30, where use rose 188%. People reporting mental health conditions or chronic pain were the most likely new users.
These trends represent demand. The Netherlands, sitting at the only accessible point of legal supply in Western Europe, sits at the intersection of that demand and a functioning commercial market. Understanding how the Dutch situation fits into the broader legal landscape, specifically what decriminalization actually means compared to other legal frameworks, matters for reading these trends accurately. What the Netherlands has is neither decriminalization nor legalization in the conventional sense. It is an unscheduled substance that operates as effectively legal because the scheduling language never covered it.
Could the Loophole Be Closed?
Several Dutch politicians have proposed closing the sclerotia gap at various points since 2008. None of the proposals advanced to a vote. The reasons are practical, political, and rooted in the Dutch drug policy tradition.
Practically, smart shops are licensed, tax-paying commercial businesses. They serve consumers who, without a legal truffle option, would turn to unregulated street markets for the same substance. The Dutch harm-reduction framework is built on the premise that regulated supply is preferable to unregulated supply for the users who will consume regardless of legal status. Closing the truffle market would eliminate the regulated channel without eliminating the demand.
Politically, the Netherlands has been moving in the direction of expanded drug regulation, not contraction. The country is currently piloting licensed cannabis retail sales through a regulated wietexperiment in several cities, a framework that runs parallel to the coffee shop tolerance policy. Closing the truffle loophole would cut against the direction of active policy work.
The European context matters too. Germany, France, and the UK all maintain psilocybin prohibition with no legal-access channels. The Netherlands' truffle market attracts tourism revenue, and the retreat sector generates employment and professional services activity. The economic case against closing the loophole is not trivial.
The current Dutch coalition government, formed in 2025, includes parties with divergent drug policy positions. The truffle issue has not featured in coalition negotiations or ministerial priorities. Smart shop trade associations maintain professional lobbying relationships with the relevant ministries. The situation looks stable.
For anyone tracking the broader US decriminalization wave from Denver outward and what it might look like at national scale, the Netherlands offers a 15-year data point. A commercially open psilocybin market, created entirely by a legislative accident, has operated without producing the public safety or public health crises that prohibition advocates predict. The political will to reverse it has not materialized.
The Bottom Line
Magic truffles are legal in the Netherlands because the 2008 Opium Act amendment banning magic mushrooms used "paddenstoelen," a term covering only the above-ground fruiting body, and never named the psilocybin-containing sclerotia that grow underground. Smart shops immediately pivoted to truffle sales, Dutch courts have consistently upheld the distinction, and the Netherlands now hosts a commercial truffle market and an openly operating retreat sector serving primarily international clients. No serious legislative effort to close the gap has advanced since 2008.
Frequently Asked Questions
Sources & References
- 1RTHM-02058·Bhave, Ashutosh (2025). “Magic of the Mushrooms: Effects of Psilocybin Decriminalization..” Journal of psychoactive drugs.Study breakdown →PubMed →↩
- 2. Source details for this reference are not yet available.